Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, prospective, randomized, controlled study of the safety and efficacy
including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in
HIV infected patients with CD4 counts >300 and HIV-1 plasma RNA >500 and <30,000 copies/ml
(PCR).